Selenium: Thyroid, Immune Function, and the Narrow Therapeutic Window

This content is for educational purposes only and is not a substitute for personalised nutrition advice from a qualified dietitian or healthcare professional.

Selenium occupies an unusual place in human nutrition. It is required in microgram quantities, orders of magnitude less than calcium, magnesium, or potassium, yet its deficiency disrupts thyroid hormone activation, antioxidant defence, and immune surveillance in ways that other minerals cannot compensate for. It also has one of the narrowest therapeutic windows of any essential nutrient: the gap between physiologically optimal and frankly toxic intake is smaller than for almost any other dietary mineral. That combination, biological indispensability, low intake requirement, and a tight upper safety margin, has made selenium one of the most debated trace elements of the past two decades.

What Selenium Does in the Body

Selenium is not biologically active on its own. Its function is mediated almost entirely through its incorporation into selenoproteins, a family of approximately 25 proteins identified in the human proteome that contain the unusual amino acid selenocysteine at their active site. Selenocysteine is structurally similar to cysteine but with selenium replacing sulphur, and this substitution dramatically alters the protein's redox chemistry, selenium is a more potent electron donor under physiological conditions, allowing selenoenzymes to perform reactions that sulphur-based enzymes cannot match.

Three selenoprotein families do most of the heavy lifting.

Glutathione peroxidases (GPx1–GPx8) are the major intracellular antioxidant enzymes that reduce hydrogen peroxide and lipid peroxides to water and harmless alcohols, using reduced glutathione as the electron donor. GPx1 sits in the cytoplasm of nearly every cell; GPx3 circulates in plasma; GPx4 is unique in being able to reduce phospholipid hydroperoxides directly within membranes, protecting cells from ferroptotic death. For a deeper look at the glutathione side of this partnership, see our overview of glutathione as a master antioxidant.

Iodothyronine deiodinases (DIO1, DIO2, DIO3) are the enzymes that activate and inactivate thyroid hormone. The thyroid gland produces mostly thyroxine (T4), a relatively inert prohormone with four iodine atoms. DIO1 (liver, kidney, thyroid) and DIO2 (brain, pituitary, brown adipose, skeletal muscle) remove an iodine from the outer ring of T4 to produce triiodothyronine (T3), the metabolically active form that binds thyroid hormone receptors. DIO3 removes an iodine from the inner ring, producing inactive reverse T3, providing a "brake" on local thyroid signalling. Without adequate selenium, T4-to-T3 conversion slows, and tissue-level hypothyroidism can occur even when serum TSH and T4 look normal.

Thioredoxin reductases (TrxR1–TrxR3) regenerate reduced thioredoxin, a small redox protein that controls dozens of signalling pathways, including DNA synthesis (via ribonucleotide reductase), apoptosis, and transcription factor activity. Thioredoxin reductases are notable for being among the few enzymes capable of reducing oxidised vitamin C and lipoic acid back to their active forms.

A handful of additional selenoproteins (selenoprotein P (the main plasma selenium transport protein), selenoprotein W (skeletal and cardiac muscle), and selenoprotein N (linked to congenital myopathies)) round out the functionally significant set.

Food Sources and the Brazil Nut Problem

Selenium content in plant foods reflects soil selenium content, which varies dramatically by geography. Wheat grown in the Great Plains of the United States or in central Canada is selenium-rich; the same variety grown in selenium-poor soils of New Zealand, Finland, parts of China, or much of Europe contains a fraction of the selenium per kilogram. Animal foods are buffered against this variability because livestock feed is often supplemented, but for plant-based eaters, geography matters.

The most concentrated common food source is the Brazil nut (Bertholletia excelsa), which can contain anywhere from roughly 50 µg to over 500 µg of selenium per nut, a tenfold range driven entirely by where the tree was grown. Brazil nuts from the central Amazon basin tend to be selenium-rich; those from peripheral plantation regions can be relatively poor. This variability is genuinely a problem for anyone using Brazil nuts as a precision selenium source: two nuts a day from one batch might deliver an optimal 100 µg dose, while two nuts from another batch could push intake past the upper safety limit. There is no practical way for a consumer to know without laboratory testing.

Other reliable sources include seafood (tuna, sardines, salmon, oysters), organ meats (kidney, liver), eggs, and selenium-fortified or selenium-naturally-rich grains. Mushrooms can be modest contributors. Vegetables and fruits are generally minor sources unless grown in selenium-rich soil.

Supplementation Forms

Supplemental selenium comes in several forms with meaningfully different pharmacokinetics.

Selenomethionine is the organic form found naturally in food. It is absorbed almost completely via the methionine transport system and incorporated non-specifically into body proteins in place of methionine, which creates a storage pool that buffers short-term intake fluctuations. It is the form most often used in clinical trials.

Sodium selenite (Se⁴⁺) and sodium selenate (Se⁶⁺) are inorganic forms. Selenite is reduced in the gut and absorbed somewhat less efficiently than selenomethionine; selenate is absorbed more efficiently than selenite but partially excreted unchanged in urine. Neither is incorporated into general body protein, so they provide a more "transient" supply that is rapidly used for selenoprotein synthesis or excreted.

Selenium-enriched yeast is Saccharomyces cerevisiae grown on a selenium-rich substrate; the yeast incorporates selenium predominantly as selenomethionine, with smaller amounts of methylselenocysteine and other organic species. Bioavailability is high and broadly similar to pure selenomethionine.

For the purposes of optimising glutathione peroxidase activity, inorganic selenite appears to plateau plasma GPx activity at a slightly lower dose than selenomethionine, because selenomethionine is "diverted" into general protein synthesis before reaching selenoprotein assembly. For long-term tissue saturation and stable status, organic forms (selenomethionine or selenium yeast) are typically preferred.

Selenium and Thyroid Disease

The thyroid gland contains more selenium per gram of tissue than any other organ, reflecting its dependence on selenoproteins for both hormone activation (deiodinases) and protection against the hydrogen peroxide generated during thyroid hormone synthesis (GPx enzymes).

Several randomised controlled trials and meta-analyses have examined selenium supplementation in Hashimoto's thyroiditis, the autoimmune condition in which thyroid peroxidase (TPO) antibodies progressively destroy thyroid tissue. A meta-analysis by Toulis et al. 2010 in Thyroid pooled four randomised trials of selenium (mainly selenomethionine 200 µg/day) versus placebo in patients with Hashimoto's. The pooled result favoured selenium for reduction in TPO antibody titres at three and six months, although the magnitude was modest and clinical endpoints (TSH normalisation, levothyroxine dose reduction, symptom scores) were less consistently affected.

More recent and larger trials, including the multicentre SELHASH study, have produced more equivocal results, selenium reduces TPO antibodies in some cohorts but not others, and the antibody reduction does not always translate to meaningful clinical improvement. The current honest summary is that selenium supplementation at 100–200 µg/day appears reasonably safe and may modestly suppress thyroid autoimmunity, but it is not a cure for Hashimoto's and should not be expected to eliminate the need for levothyroxine in established disease.

In Graves' disease, selenium supplementation (typically 200 µg/day for six months) has been studied as an adjunct to standard antithyroid drugs and has shown benefit for mild Graves' orbitopathy in particular, with improved quality-of-life scores and a slower progression of eye disease in one well-conducted European trial. The mechanism is presumed to involve selenium's antioxidant effects on orbital fibroblasts.

For broader context on interpreting thyroid laboratory results, including the often-overlooked free T3 to free T4 ratio that reflects deiodinase activity, see this guide to reading a thyroid panel. For a complementary view on dietary and lifestyle approaches to thyroid autoimmunity, the protocols outlined in this overview of natural approaches to Hashimoto's provide useful additional reading.

Immune Function

Selenium status influences both innate and adaptive immunity. Selenoproteins are highly expressed in immune cells, and selenium deficiency has been associated with impaired neutrophil function, reduced T-cell proliferation in response to antigen, and increased viral mutation rates in deficient hosts, the latter observed initially in Keshan disease (a selenium-deficiency cardiomyopathy in parts of China linked to coxsackievirus B) and subsequently in influenza and HIV models.

Whether selenium supplementation in selenium-replete adults provides additional immune benefit is less clear. Trials in critically ill patients with sepsis have shown mixed results, some signals of mortality reduction in earlier studies, but more recent and rigorously designed trials such as REDOXS and the larger meta-analyses have not consistently confirmed benefit. The conservative interpretation is that correcting deficiency matters; supplementing past adequacy does not appear to confer additional immune protection.

Zinc and selenium are often discussed together in immune contexts because both are required for normal T-cell function; a separate review of zinc's immune and cognitive roles covers that side of the trace-mineral picture in more depth.

The SELECT Trial and Cancer Prevention

For two decades, observational epidemiology suggested that higher selenium status was associated with lower risk of several cancers, particularly prostate, lung, and colorectal. Small randomised trials, most notably the Nutritional Prevention of Cancer (NPC) trial published by Clark and colleagues in 1996, appeared to confirm a protective signal, a secondary analysis found a 60-plus percent reduction in prostate cancer incidence in the selenium-supplemented arm.

This evidence motivated the SELECT trial, the Selenium and Vitamin E Cancer Prevention Trial, one of the largest cancer chemoprevention studies ever conducted. SELECT randomised over 35,000 men aged 50 or older (55 for African American men) to selenium (200 µg/day as L-selenomethionine), vitamin E (400 IU/day), both, or placebo. The primary endpoint was prostate cancer incidence.

The result, reported by Lippman et al. 2009 in JAMA, was unambiguously negative. Neither selenium alone, vitamin E alone, nor the combination reduced prostate cancer incidence. Follow-up analyses raised the further concern that vitamin E supplementation was associated with a small but statistically significant increase in prostate cancer incidence, and selenium was associated with a non-significant increase in type 2 diabetes risk in baseline selenium-replete men.

The negative SELECT result reshaped the field's view of selenium. The most likely explanation for the discrepancy with earlier trials is that NPC participants started from lower baseline selenium status, while SELECT participants were largely selenium-replete to start with. The implication is that selenium's protective effects, if they exist, occur on the rising slope of the dose-response curve, between deficient and adequate intake, and that pushing intake above adequacy in already-replete populations confers no benefit and may carry small risks.

A similar U-shaped pattern has emerged for cardiovascular and all-cause mortality in cohort studies, with the lowest mortality in those with plasma selenium around 120–140 ng/mL and rising mortality at both lower and higher extremes.

Selenium Status by Region

Selenium status varies geographically more than almost any other nutrient.

• New Zealand has historically been one of the lowest-selenium populations globally, with mean plasma selenium often around 60–80 ng/mL, sufficient to avoid Keshan-style deficiency but low enough that GPx activity is sub-maximal. Wheat imports from selenium-rich Australian sources have improved the picture in recent decades.
• The United States and Canada sit on selenium-rich agricultural soils, with mean plasma selenium typically 130–150 ng/mL and routine supplementation rarely necessary.
• Australia generally falls in the adequate-to-high range due to selenium-rich wheat-growing regions, with mean intakes for adults estimated at roughly 60–80 µg/day for women and 80–120 µg/day for men. The Australian and New Zealand Nutrient Reference Values set the RDI at 60 µg/day for women and 70 µg/day for men.
• Parts of China and central Europe show much greater variability, with selenium-deficient belts producing both Keshan disease and Kashin-Beck disease historically.

Selenosis: The Narrow Therapeutic Window

Selenium has one of the lowest tolerable upper intake levels of any essential nutrient. The NHMRC and US Institute of Medicine both set the Upper Level of Intake (UL) at 400 µg/day for adults, reflecting evidence of chronic selenosis above this threshold.

Selenosis presents with a recognisable but easily missed cluster of symptoms: brittle, ridged, or breaking fingernails and toenails; hair loss (often patchy); a distinctive garlic-like breath odour due to dimethylselenide excretion through the lungs; gastrointestinal upset; and, in severe cases, peripheral neuropathy. Case reports of acute selenosis from over-formulated supplements, most notoriously a 2008 US incident in which a manufacturing error produced supplements containing roughly 200 times the labelled dose, describe severe symptoms developing over weeks.

The narrowness of the safety window means that combining a selenium supplement with regular consumption of high-selenium foods (especially Brazil nuts) can plausibly push total intake into the borderline range. Someone taking a 200 µg supplement and eating three or four Brazil nuts daily could realistically receive 400–700+ µg/day, depending on nut origin. This is the practical reason most clinical nutritionists advise choosing either a measured supplement or Brazil nuts as the selenium source, rather than both.

Australian Intake Context and Practical Considerations

For most Australian adults consuming a varied diet that includes seafood, eggs, meat or poultry, and wheat-based products, selenium intake is adequate without supplementation. Vegetarians and vegans, particularly those relying mainly on locally-grown produce from selenium-poor regions, may benefit from periodic intake review. Two to three Brazil nuts from a known source, or 100 µg/day of selenomethionine, covers the requirement comfortably for most adults.

Selenium status can be assessed via plasma or serum selenium (reflects recent intake) or plasma selenoprotein P (reflects longer-term status and is the more sensitive marker of functional repletion). Whole-blood selenium reflects very long-term status due to incorporation into red cell proteins. The same logic of measure-before-supplement applies here as it does for iron bioavailability and ferritin interpretation, function-relevant markers tell a clearer story than crude serum levels.

As with other fat- and water-soluble nutrients that interact in complex ways (see, for example, the overview of vitamin K2 (MK-7) evidence) the principle is to address measurable inadequacy rather than reflexively layer supplements onto an already-replete diet.

Honest Evidence Summary

The broad-strokes picture, as outlined in Rayman's 2012 Lancet review of selenium and human health, is this:

• Selenium is essential, and frank deficiency disrupts thyroid hormone activation, antioxidant defence, and immune function.
• Correcting deficiency reliably restores selenoprotein function; supplementing past adequacy does not appear to confer additional benefit and may carry risks at the upper extreme.
• The strongest clinical case for therapeutic selenium supplementation is in autoimmune thyroid disease (modest, consistent reduction in TPO antibodies) and possibly mild Graves' orbitopathy.
• The cancer chemoprevention hypothesis was definitively not supported in selenium-replete populations by SELECT.
• The therapeutic window is narrow, 400 µg/day is a hard upper bound for chronic intake.

Key Takeaways

• Selenium functions via roughly 25 selenoproteins, including GPx (antioxidant defence), deiodinases (T4→T3 conversion), and thioredoxin reductase.
• Selenomethionine and selenium-enriched yeast provide stable, well-absorbed organic selenium; selenite and selenate are inorganic alternatives with different kinetics.
• Brazil nut selenium content varies roughly tenfold depending on soil of origin, making them imprecise as a primary supplement.
• Hashimoto's trials show modest reductions in TPO antibody titres with 100–200 µg/day selenium; clinical benefit is more uncertain.
• The SELECT trial showed no cancer prevention benefit in selenium-replete men and a possible signal for increased diabetes risk.
• Australian intakes are generally adequate; New Zealand status has historically been lower.
• Selenosis (nail changes, hair loss, garlic breath, neuropathy) occurs above approximately 400 µg/day chronic intake, one of the narrowest safety windows of any essential nutrient.

Selenium is a case study in why "more" is rarely "better" in micronutrient science. Adequate intake supports a small but irreplaceable set of biological functions; excess intake offers no further benefit and a real, if modest, increase in risk.